Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
RETA was delisted on the 25th of September, 2023.
164 hedge funds and large institutions have $1.46B invested in Reata Pharmaceuticals, Inc. Class A Common Stock in 2019 Q3 according to their latest regulatory filings, with 26 funds opening new positions, 65 increasing their positions, 39 reducing their positions, and 20 closing their positions.
67% more repeat investments, than reductions
Existing positions increased: 65 | Existing positions reduced: 39
30% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 20
4% more funds holding
Funds holding: 158 → 164 (+6)
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
12% less capital invested
Capital invested by funds: $1.66B → $1.46B (-$200M)
61% less call options, than puts
Call options by funds: $21.3M | Put options by funds: $54.7M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$30.9M |
| 2 |
DFO
Duquesne Family Office
New York
|
+$14.7M |
| 3 |
AA
Alta Advisers
London,
United Kingdom
|
+$13.6M |
| 4 |
SPC
Slate Path Capital
New York
|
+$10.2M |
| 5 |
Norges Bank
Oslo,
Norway
|
+$10.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$52.4M |
| 2 |
Millennium Management
New York
|
-$19.5M |
| 3 |
EA
Emerald Advisers
Leola,
Pennsylvania
|
-$8.87M |
| 4 |
EMFAT
Emerald Mutual Fund Advisers Trust
Leola,
Pennsylvania
|
-$7.86M |
| 5 |
PM
Prosight Management
Dallas,
Texas
|
-$5.29M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
GC
176
Guggenheim Capital
Chicago,
Illinois
| – | -$218K | -2,314 | Closed |
|
177
Prudential Financial
Newark,
New Jersey
| – | -$206K | -2,186 | Closed |
|
|
MAM
178
Meeder Asset Management
Dublin,
Ohio
| – | -$34K | -360 | Closed |
|
|
OIA
179
OneDigital Investment Advisors
Overland Park,
Kansas
| – | -$25K | -270 | Closed |
|
|
PHK
180
Point72 Hong Kong
Hong Kong
| – | -$16K | -168 | Closed |
|
|
AA
181
AlphaMark Advisors
Ft. Wright,
Kentucky
| – | -$11K | -115 | Closed |
|
|
PCP
182
Proficio Capital Partners
Newton,
Massachusetts
| – | -$10K | -107 | Closed |
|
RETA Hedge Fund Activity: Q3 2019 in Review
164 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) for Q3 2019, worth a combined $1.46B — down 12% from $1.66B a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new RETA positions and 20 closed out — a net gain of 6 holders — while 65 added to existing stakes and 39 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $30.9M. The largest seller was Farallon Capital Management, cutting an estimated $52.4M.
- 164 institutional investors held Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) as of Q3 2019, up from 158 in Q2 2019.
- Funds reported $1.46B of Reata Pharmaceuticals, Inc. Class A Common Stock stock for Q3 2019, down 12% quarter-over-quarter.
- 26 funds opened new Reata Pharmaceuticals, Inc. Class A Common Stock positions in Q3 2019 and 20 closed out, a net change of +6 holders.
- The largest Reata Pharmaceuticals, Inc. Class A Common Stock buyer in Q3 2019 was T. Rowe Price Associates, an estimated $30.9M added.
- The largest Reata Pharmaceuticals, Inc. Class A Common Stock seller in Q3 2019 was Farallon Capital Management, an estimated $52.4M sold.
Based on aggregated 13F filings for Q3 2019.